Language Select
Varian Logo

Press Releases

November 03, 2017
Varian (NYSE: VAR), the world leader in radiotherapy equipment and software, has been selected to equip the greater Copenhagen region’s two radiation oncology departments with modern treatment systems over the next several years. Linear accelerators at the city’s Rigshospitalet and Herlev Hospital oncology departments will be replaced with 15 advanced Varian TrueBeam™ and Halcyon™ treatment machines and two ViewRay MRIdian® MR-Guided Linac systems, which also formed part of the tender. Varian is booking an order for the first four of the TrueBeam™ systems in the current fiscal quarter. Read more
November 01, 2017
Representing the latest step in Varian Medical Systems’ (NYSE: VAR) efforts to expand the availability of high quality cancer care globally, the company announced a 71-year-old male with prostate cancer became the first patient in Australia to be treated on the Halcyon™ system at Radiation Oncology Centres (ROC) in Toowoomba by Brisbane-based Icon Group. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head & neck, and many other forms of cancer. Read more
October 30, 2017
Varian Medical Systems (NYSE: VAR) today announced it has named Terilyn Juarez Monroe as Chief People Officer, senior vice-president, Human Resources effective October 30, 2017. Ms. Monroe, 50, is replacing Wendy Scott who is retiring after serving in this same role at Varian for 13 years. Read more
October 25, 2017
Varian Medical Systems (NYSE: VAR) today announced it has been selected to install a ProBeam® four-room proton therapy system in the new Guangzhou Concord Cancer Hospital. Varian will also... Read more
October 25, 2017
Varian Medical Systems (NYSE: VAR) today announced it has been selected by Penn Medicine to install a Varian ProBeam® Compact single-room proton therapy system in a new cancer treatment center.... Read more
October 25, 2017
Fourth Quarter 2017 Summary Oncology gross orders grew 7% Booked 23 Halcyon™ orders, 50 orders since May launch GAAP net earnings per diluted share from continuing operations of $0.89 including... Read more
October 24, 2017
Varian (NYSE: VAR) today announced five patients with brain cancer became the first patients in the US to be treated using the company's HyperArc™ High Definition Radiotherapy (HDRT), a new type... Read more
October 23, 2017
A 71-year-old eye cancer patient has become the first person in the UK, and among the first in the world, to be treated using HyperArc™ high definition radiotherapy (HDRT) technology from Varian... Read more
October 17, 2017
Varian (NYSE: VAR) today announced an 80-year-old male with head & neck cancer became the first patient in Europe to be treated on the Halcyon™ system at University Hospitals Leuven (UZ Leuven)... Read more
October 02, 2017
Varian (NYSE: VAR), global leader in radiotherapy treatments systems and software, is announcing the publication of its annual Sustainability Report, detailing the company's policies and... Read more

Corporate Communications Contact

Mark Plungy
Director, Public Relations

Investor Relations Contact

Mike Bruff
SVP, Investor Relations